PD-1/PD-L1 interaction

Class

Small-molecule PD-1/PD-L1 interaction inhibitor

Pathway

Immune checkpoint inhibitor; orally available small molecule that blocks the PD-1/PD-L1 protein-protein interaction to restore anti-tumor T-cell activity

Programmed death-1 (PD-1) is a receptor expressed on activated T lymphocytes, the immune cells responsible for recognizing and destroying abnormal cells, including tumor cells. Its ligand, PD-L1, is displayed on the surface of many tumor cells and on some normal tissues. When PD-L1 engages PD-1, it delivers an inhibitory signal that dampens T-cell activity, a mechanism the body normally uses to prevent excessive immune responses and autoimmunity. Tumors exploit this checkpoint by upregulating PD-L1, effectively disguising themselves from immune attack. Blocking the PD-1/PD-L1 interaction interrupts this inhibitory signal, allowing T cells to remain active against tumor cells; this is the founding principle of immune checkpoint inhibition in oncology. While this mechanism is most established with injectable antibody therapies, small molecules designed to disrupt the same protein-protein interaction pursue the identical biological goal through an orally available format, which may offer differences in dosing convenience, tissue distribution, and manufacturing compared with antibody-based approaches. Because the checkpoint is relevant across many tumor types that use PD-L1 upregulation as an immune evasion strategy, this mechanism broadly matters across solid tumor oncology and some hematologic malignancies.